LGVN - Longeveron Inc.
After hours:
Chart Events
Slow Stochastic
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 3.1600 |
| Open | 3.2200 |
| Bid | 3.1300 x 800 |
| Ask | 3.2500 x 1000 |
| Day's Range | 3.2000 - 3.3000 |
| 52 Week Range | 2.5000 - 8.7300 |
| Volume | |
| Avg. Volume | 155,773 |
| Market Cap | 68.516M |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0300 |
| Earnings Date | May 14, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.60 |
Fair Value
Related Research
- InvestorPlace
LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates
Longeveron (NASDAQ:LGVN) just reported results for the first quarter of 2023. Longeveron reported a loss per share of 22 cents. This was slightly worse than the analyst estimate for a loss of 21 cents. The company reported revenue of $279,000. This was also worse than the analyst estimate for revenue of $300,000. You can read the full Longeveron press release here. On the date of publication, Sarah Smith did not have (either directly or indirectly) any positions in the securities mentioned in th
- Zacks Small Cap Research
LGVN: Announces Results and Progress on a Devastating Disease
By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) announced 1Q 2023 earnings results today and the following are the highlights: • Revenues came in at $0.3 million, as expected, which comes from the company’s Bahamas Registry Trial. • Earnings came in showing a loss of $0.22 per share, roughly inline with expectations. • General and administrative
GlobeNewswireLongeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results
-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit -- -- First patient dosed in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty in Japan -- -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing regenerative medicines for unme
BenzingaLongeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-Free
Longeveron Inc (NASDAQ: LGVN) announced new long-term follow-up data from its ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS). The data showed that 100% of the ten patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery. To date, All ten patients enrolled in the study have been monitored for at least 3.5 years after treatment with Lomecel-BTM.
- GlobeNewswire
Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome
- Children in the ELPIS I trial had 100% survival up to 5 years of age after receiving Lomecel-BTM compared to 20% mortality rate observed from historical control data - - Data reinforce potential survival benefit of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS) - - Enrollment ongoing in Phase 2a ELPIS II trial - - Lomecel-BTM has Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation for HLHS Indication - MIAMI, May 09, 2023 (GLOBE NEWSWIR
- GlobeNewswire
Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023
Live conference call on Friday, May 12 at 8:30 a.m. ETMIAMI, May 08, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its first quarter 2023 financial results on Friday, May 12, 2023 before the open of the U.S. financial markets. Management will host a conference call to discuss the Company’s financial results and prov
- GlobeNewswire
Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan
-- The study’s primary objective is to evaluate the safety of Lomecel-B™ in Japan’s elderly population -- -- First-in-human clinical trial of Lomecel-B™ in Japan -- -- Study will also assess efficacy endpoints expanding Longeveron’s database of Lomecel-B™’s physiologic effects in individuals of older age -- MIAMI, April 19, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medica
Simply Wall St.Longeveron (NASDAQ:LGVN shareholders incur further losses as stock declines 18% this week, taking one-year losses to 51%
Investing in stocks comes with the risk that the share price will fall. Anyone who held Longeveron Inc. ( NASDAQ:LGVN...
- GlobeNewswire
Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-- Full results from ELPIS I trial published in European Heart Journal Open – -- First patient to be randomized in Japan Aging-Related Phase 2 study in Q1 – -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, March 10, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the fourth quart
- Zacks Small Cap Research
LGVN: Longeveron Continues Progress Toward Important Treatments
By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a clinical-stage biotechnology company developing cellular therapies for age-related chronic diseases, while also attempting to address other life-threatening conditions. Longeveron operates with the central belief that the same cells in human bodies that promote healing and function, such as tissue
- InvestorPlace
Insiders Just Bought $1 Million of This Deep Value Tech Stock
On Monday, SEC filings revealed that three executives had bought an enormous amount of iHeartMedia (NASDAQ:IHRT) stock. Together, the firm’s CEO, CFO and chief accounting officer snapped up over 190,000 shares worth $1.05 million. It’s a fascinating turn of events. iHeartMedia’s stock is down almost 75% since 2022, and shares trade as a stub on top of a massive debt pile. Any good news could send shares up 100%… 200%… 500% or more. I’ve long noted that CEO and CFO buying is a strong positive sig
- GlobeNewswire
Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
Live conference call on Friday, March 10 at 8:30 a.m. ETMIAMI, March 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its fourth quarter and full year 2022 financial results on Friday, March 10, 2023 before the open of the U.S. financial markets. Management will host a conference call to discusss the Company’s fina
- GlobeNewswire
Longeveron Appoints Wa’el Hashad as Chief Executive Officer
Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over 35 years of experience with focus on drug approval and commercialization, mergers and acquisitions, and business development MIAMI, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for rare pediatric disease, aging-related conditions, a
- Simply Wall St.
Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- Zacks Small Cap Research
LGVN: Longeveron Posts Positive Results for Life-Threatening Condition
By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT LGVN (NASDAQ:LGVN) is a clinical stage biotech company that is using cutting edge cellular technology for various major medical conditions that we believe is undervalued by investors who are not appreciating the game-changing potential that the signature treatment, Lomecel-B, has to impact people’s lives. That belief was
- GlobeNewswire
Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
-- Full results published in European Heart Journal Open -- -- Study met primary safety endpoint -- -- All patients alive, transplant-free, and maintained expected rate of growth one year after treatment -- -- Data supports ongoing clinical development of Lomecel-BTM for HLHS, currently being evaluated in a Phase 2a trial -- MIAMI, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines
- GlobeNewswire
UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a corporate update highlighting the Company’s strategic priorities and anticipated milestones for 2023. “This past year Longeveron m
- GlobeNewswire
Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a corporate update highlighting the Company’s strategic priorities and anticipated milestones for 2023. “This past year Longeveron m
- GlobeNewswire
Longeveron to Participate in Upcoming 2022 Investor Conferences
MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that Company leadership will participate in three upcoming investor conferences. A.G.P.’s Virtual Biotech ConferenceFormat: One-on-one Meetings Date: Wednesday, November 30, 2022Location: Virtual The Benchmark Company 11th Annual Discovery One-on-One Investor ConferenceFormat: One-on-
- Simply Wall St.
Longeveron Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
Longeveron ( NASDAQ:LGVN ) Third Quarter 2022 Results Key Financial Results Net loss: US$5.24m (loss widened by 8.0...
- GlobeNewswire
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results
-- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease -- -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for
- Zacks Small Cap Research
LGVN: Making Exciting Progress
By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a clinical stage biotech company that is using cutting edge cellular technology to treat a rare heart disease and the impacts of aging. Longeveron reported a 3Q 2022 loss of $0.25/per share, in line with the same quarter last year and within the range of expectations. More importantly, on a conference
GlobeNewswireLongeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease
MIAMI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the completion of enrollment in its Phase 2a trial of Lomecel-BTM in patients with mild Alzheimer’s Disease (AD). “We are pleased to have completed enrollment in our Phase 2a study of Lomecel-BTM for Alzheimer’s Disease. We look forward to building on our Phase 1b study, which met its
- GlobeNewswire
Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022
Live conference call on Monday, November 14 at 8:30 a.m. ESTMIAMI, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022 before the open of the U.S. financial markets. Management will host a conference call to discuss the Company’s financial resu
- Simply Wall St.
Investing in Longeveron (NASDAQ:LGVN) a year ago would have delivered you a 13% gain
Some Longeveron Inc. ( NASDAQ:LGVN ) shareholders are probably rather concerned to see the share price fall 36% over...